about
Microbiological Characteristics and Predictive Factors for Mortality in Pleural Infection: A Single-Center Cohort Study in KoreaAcute respiratory distress syndrome and chemical burns after exposure to chlorine-containing bleach: a case reportBelotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma.Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer.Predictors of Default from Treatment for Tuberculosis: a Single Center Case-Control Study in Korea.Different characteristics associated with intensive care unit transfer from the medical ward between patients with acute exacerbations of chronic obstructive pulmonary disease with and without pneumoniaOnce-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.Clinical factors associated with weaning failure in patients requiring prolonged mechanical ventilation.Review of Sarcoidosis in a Province of South Korea from 1996 to 2014Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial.Inverse association of peripheral blood CD4(+) invariant natural killer T cells with atopy in human asthma.What is Currently the Best for Adenocarcinoma without Driver Mutation?Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung AdenocarcinomaClinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung CancerPredictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancerSuperior vena cava syndrome with extensive collateral vessels
P50
Q28553554-CC92C64C-4B97-4581-A9A7-CFF9F7284C78Q28816960-45D2F5C1-C626-4150-942C-14DA6A93AD7DQ33434872-63CD84BA-D82C-47F5-A4C7-7000A2DC44DFQ34440066-D47C1365-509F-477F-9E3B-A258F818770BQ35663566-5CC2E9F3-22BD-4306-9ADA-DE038D984D94Q36187118-B51B9102-8D80-455F-93A9-D9BC23D627FEQ36247912-24D2BD73-B417-4AD1-B59B-4E128B5C6756Q36439420-7E9635C9-707B-4585-9C8C-251497A47CECQ36509978-37AFB6FF-D095-4B4A-9FEC-719C1F5930BFQ36948992-E5477D5C-3C66-4140-9AC1-D085A8F65DF7Q37404917-D903E165-B732-49CE-8EC3-15E968152214Q37636961-74F26175-02CB-4833-A08E-A484B29507C2Q41124310-7698C0DA-8606-4F88-8706-998E7ACDEEA7Q47137872-0E8160F3-19D9-451E-AE58-0CC19797A221Q52675550-C5A0DF68-FCAA-42D3-929B-7F80B8ED9C68Q53121782-A6914390-851B-4D1A-93EB-88F0CCAA3986Q53492279-F801865B-00A2-4EC9-B634-1A00911EE0E5Q55453644-97E68FAA-5D30-448A-8048-D81D386C5FABQ57213186-D432BB3D-7AF4-44AE-8A74-653D7C4E7304Q60956984-A86D56FB-04E0-4E7A-90A8-2A36DF7A6020Q64106056-6DC2EF64-AF0A-4B5A-881B-1DCC56F83B27Q90832360-2F9B4340-6CB5-4636-AB38-525D11140380
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cheol Kyu Park
@ast
Cheol Kyu Park
@en
Cheol Kyu Park
@es
Cheol Kyu Park
@nl
type
label
Cheol Kyu Park
@ast
Cheol Kyu Park
@en
Cheol Kyu Park
@es
Cheol Kyu Park
@nl
prefLabel
Cheol Kyu Park
@ast
Cheol Kyu Park
@en
Cheol Kyu Park
@es
Cheol Kyu Park
@nl
P106
P1153
56424318200
P31
P496
0000-0001-8701-0786